Logo image of PRFX

PAINREFORM LTD (PRFX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRFX - IL0011651580 - Common Stock

0.85 USD
+0 (+0.06%)
Last: 1/9/2026, 8:18:21 PM
0.89 USD
+0.04 (+4.71%)
After Hours: 1/9/2026, 8:18:21 PM
Fundamental Rating

2

Taking everything into account, PRFX scores 2 out of 10 in our fundamental rating. PRFX was compared to 190 industry peers in the Pharmaceuticals industry. The financial health of PRFX is average, but there are quite some concerns on its profitability. PRFX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRFX has reported negative net income.
PRFX had a negative operating cash flow in the past year.
In the past 5 years PRFX always reported negative net income.
PRFX had a negative operating cash flow in each of the past 5 years.
PRFX Yearly Net Income VS EBIT VS OCF VS FCFPRFX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

PRFX has a worse Return On Assets (-130.69%) than 83.33% of its industry peers.
PRFX has a Return On Equity of -172.78%. This is in the lower half of the industry: PRFX underperforms 71.35% of its industry peers.
Industry RankSector Rank
ROA -130.69%
ROE -172.78%
ROIC N/A
ROA(3y)-162.59%
ROA(5y)-109.71%
ROE(3y)-336.21%
ROE(5y)-214.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRFX Yearly ROA, ROE, ROICPRFX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRFX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRFX Yearly Profit, Operating, Gross MarginsPRFX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

PRFX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRFX has been increased compared to 5 years ago.
There is no outstanding debt for PRFX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRFX Yearly Shares OutstandingPRFX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
PRFX Yearly Total Debt VS Total AssetsPRFX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -10.82, we must say that PRFX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PRFX (-10.82) is worse than 73.44% of its industry peers.
PRFX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.82
ROIC/WACCN/A
WACCN/A
PRFX Yearly LT Debt VS Equity VS FCFPRFX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

PRFX has a Current Ratio of 1.59. This is a normal value and indicates that PRFX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PRFX (1.59) is worse than 69.79% of its industry peers.
PRFX has a Quick Ratio of 1.59. This is a normal value and indicates that PRFX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.59, PRFX perfoms like the industry average, outperforming 40.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.59
PRFX Yearly Current Assets VS Current LiabilitesPRFX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

PRFX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.23%, which is quite impressive.
EPS 1Y (TTM)81.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PRFX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.63% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.91%
EPS Next 2Y24.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRFX Yearly EPS VS EstimatesPRFX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRFX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRFX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRFX Price Earnings VS Forward Price EarningsPRFX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRFX Per share dataPRFX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PRFX's earnings are expected to grow with 24.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.63%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PRFX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PAINREFORM LTD

NASDAQ:PRFX (1/9/2026, 8:18:21 PM)

After market: 0.89 +0.04 (+4.71%)

0.85

+0 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13
Earnings (Next)N/A N/A
Inst Owners0.42%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.33M
Revenue(TTM)N/A
Net Income(TTM)-14.59M
Analysts43.33
Price TargetN/A
Short Float %3.28%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 2.52
EV/EBITDA N/A
EPS(TTM)-32.16
EYN/A
EPS(NY)-35.99
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS2.15
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -130.69%
ROE -172.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-162.59%
ROA(5y)-109.71%
ROE(3y)-336.21%
ROE(5y)-214.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.59
Altman-Z -10.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
EPS Next Y38.91%
EPS Next 2Y24.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.81%
OCF growth 3YN/A
OCF growth 5YN/A

PAINREFORM LTD / PRFX FAQ

What is the ChartMill fundamental rating of PAINREFORM LTD (PRFX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRFX.


What is the valuation status of PAINREFORM LTD (PRFX) stock?

ChartMill assigns a valuation rating of 1 / 10 to PAINREFORM LTD (PRFX). This can be considered as Overvalued.


Can you provide the profitability details for PAINREFORM LTD?

PAINREFORM LTD (PRFX) has a profitability rating of 0 / 10.


How financially healthy is PAINREFORM LTD?

The financial health rating of PAINREFORM LTD (PRFX) is 5 / 10.